Results 151 to 160 of about 69,426 (314)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database [PDF]

, 2023
Dongxuan Li, Jinghui Gou, Jun Zhu, Tongyan Zhang, Feng Liu, Dao‐Jun Zhang, Li‐Yang Dai, Wenjun Li, Qinglong Liu, Chunmeng Qin, Qian Du, Songqing Liu   +11 more
openalex   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth, Joseph F. Merola, Richard Furie, Kenneth Kalunian, Ronald F. van Vollenhoven, Juanita Romero‐Diaz, Qianyun Li, Weihong Yang, Catherine Barbey   +8 more
wiley   +1 more source

Facing the Trial of Internationalizing Clinical Trials to Developing Countries: Some Evidence from Mexico [PDF]

In pursuit of innovation, developing countries play an increasingly relevant role for multinational pharmaceutical firms. Driven partly by cost considerations but also by some host country-specific scientific and technological factors, global drug ...
Santiago-Rodriguez, Fernando
core  

The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases [PDF]

Zhaorui Wang, Linlin Guo, Youfu He, Baiquan Zhang, Yang Wang, Juan Ding   +5 more
openalex   +1 more source

The association between ACE inhibitors and psoriasis based on the drug-targeted Mendelian randomization and real-world pharmacovigilance analyses

, 2023
Qiubai Jin, Feihong Ren, Ping Song
openalex   +1 more source

Withdrawn 2.0—update on withdrawn drugs with pharmacovigilance data [PDF]

, 2023
Kathleen A. Gallo, Andrean Goede, Oliver-Andreas Eckert, Björn-Oliver Gohlke, Robert Preißner   +4 more
openalex   +1 more source

Making the Old New Again Through the Process of Recombinant Innovation

Journal of Product Innovation Management, EarlyView.
ABSTRACT Academic Summary Recombinant innovation—the process through which atypical and unexpected combinations of knowledge generate novel outcomes—is a critical driver of organizational distinctiveness and market transformation. While prior research has focused on firm‐ and industry‐level mechanisms, less attention has been given to multilevel ...
Vittoria Magrelli, Josip Kotlar, Alfredo De Massis, Federico Frattini, Antonio Messeni Petruzzelli   +4 more
wiley   +1 more source

Pharmacovigilance

Journal of the Royal College of Physicians of London, 1992
openaire   +2 more sources

Learning the effects of psychotropic drugs during pregnancy using real-world safety data: a paradigm shift toward modern pharmacovigilance

, 2018
Angela Lupattelli, Olav Spigset, Hedvig Nordeng   +2 more
openalex   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source